Table 3.
Descriptive statistics of stress and anxiety symptoms among the respondents and differences in the levels of stress and anxiety before and after the administration of the first dose COVID-19 vaccine.
| Variables | Samples | MD (IQR) before Vaccination | MD (IQR) after Vaccination | z of Wilcoxon Signed-Rank Test | p | r |
|---|---|---|---|---|---|---|
| Stress | Whole sample (n = 250) | 5.0 (1.0–8.0) | 4.0 (1.0–7.0) | −3.81 | 0.001 | 0.17 |
| Anxiety | 3.0 (1.0–7.0) | 5.0 (1.0–7.0) | −0.53 | 0.597 | 0.02 | |
| Stress | Normal anxiety (n = 126) | 2.0 (0.0–4.0) | 4.5 (0.0–6.3) | −3.57 | 0.001 | 0.16 |
| Anxiety | 1.0 (0.0–2.0) | 5.0 (0.0–7.0) | −8.24 | 0.001 | 0.37 | |
| Stress | Mild anxiety (n = 31) | 4.0 (3.0–7.0) | 3.0 (3.0–5.0) | −1.28 | 0.201 | 0.06 |
| Anxiety | 4.0 (4.0–5.0) | 3.0 (3.0–5.0) | −2.70 | 0.007 | 0.12 | |
| Stress | Moderate–severe anxiety (n = 93) | 8.0 (7.0–14.0) | 5.0 (2.0–8.0) | −7.13 | 0.001 | 0.32 |
| Anxiety | 8.0 (7.0–13.0) | 6.0 (1.0–8.0) | −7.27 | 0.001 | 0.33 |
MD: median; IQR: interquartile range; r: reflects effect size. N.B. Groups are described based on prevaccine levels of anxiety on the anxiety subscale of the Depression Anxiety Stress Scale 21.